[Tobacco use prevention and cessation in the dental practice].
This is the fourth part of a series of publications from the Swiss task force named "Smoking--intervention in the private dental office" on the topic "tobacco use and dental medicine". It presents the implementation of tobacco use prevention and cessation in the dental practice. Next to the optimal performance of plaque control, tobacco use cessation has become the most important measure for the treatment of periodontal diseases. In contrast to general medicine practice, the dental practice team is seeing its patients regularly and is therefore capable of helping their patients quit tobacco use. Tobacco dependence consists of both a physical and a psychological dependence. Therefore, the combination of pharmacotherapy with behavior change counseling is recommended. The use of brief Motivational Interviewing (BMI) for tobacco use short interventions in the dental practice appears to be suitable. Nicotine replacement therapy (NRT) is the treatment of choice for the dental practice team because both Varenicline and Bupropion SR have to be prescribed by physicians.
Ramseier
Christoph A
CA
Dept. of Periodontics and Oral Medicine School of Dentistry, University of Michigan, 1011 N. University Avenue, Ann Arbor 48109, USA. ramseier@umich.edu
Bornstein
Michael M
MM
Saxer
Ulrich P
UP
Klingler
Karl
K
Walter
Clemens
C
D001521:Behavior Therapy / Q000379:methods; D001552:Benzazepines / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D003812:Dentist-Patient Relations; D006284:Health Plan Implementation; D006801:Humans; D007406:Interview, Psychological / Q000379:methods; D009062:Mouth Neoplasms / Q000209:etiology; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D009765:Obesity / Q000523:psychology; D010518:Periodontitis / Q000209:etiology; D024382:Professional Role; D011810:Quinoxalines / Q000627:therapeutic use; D020377:Self Efficacy; D011795:Surveys and Questionnaires; D020340:Tobacco Use Cessation / Q000379:methods / Q000523:psychology; D014029:Tobacco Use Disorder / Q000150:complications / Q000628:therapy*; D000068580:Varenicline; D015430:Weight Gain
D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline